Navigation Links
Adding bavituximab to second-line chemotherapy doubles response rate
Date:9/6/2012

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

Docetaxel is the standard second-line treatment for stage IIIB and stage IV NS-NSCLC patients. Researchers in this phase II, nine center, double-blind, randomized study evaluated the efficacy and safety of docetaxel plus a placebo (control arm) versus docetaxel plus either 1 mg or 3 mg bavituximab. The 117 evaluable patients were randomized to receive one of the three regimens every 21 days for up to six cycles. Patients received the same regimen for each cycle.

The overall response rate for the 1 mg bavituximab arm was 15 percent and 17.9 percent in the 3 mg arm, approximately double the control arm rate of 7.9 percent. Median progression-free survival was 4.2 and 4.5 months for the bavituximab arms, respectively, compared to three months for the control arm.

The trial was unblinded after 18 months, at which point the median overall survival had been reached in the control arm at 5.4 months (61 percent of patients died); however, neither bavituximab arms had reached median overall survival (fewer than 35 percent of patients died).

"This rigorous phase II trial demonstrates that not only is bavituximab well tolerated when given with docetaxel but it improves response rates, progression free survival and overall survival of second-line chemotherapy in patients with advanced NSCLC," said David Gerber, MD, lead author of the study and an assistant professor of internal medicine at University of Texas Southwestern Medical Center in Dallas who specializes in lung cancer treatment. "If a phase III trial confirms these findings, bavituximab could become a major component of standard treatment for patients with this challenging disease."
'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Adding Plavix to Aspirin Doesnt Help Guard Against Second Stroke: Study
2. Adding More Neurosurgeons Could Cut Traffic Deaths: Study
3. Adding Vitamin B12 to Standard Drugs Might Help Fight Hepatitis C
4. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
5. Newer Second-Line Diabetes Drug May Outperform Older Meds
6. Immunodeficient patients with secondary lung disease benefit from combined chemotherapy
7. Breast cancer patients who lack RB gene respond better to neoadjuvant chemotherapy
8. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
9. RLIP76 contributes to pancreatic cancer cell resistance to chemotherapy and radiation
10. Pediatric regime of chemotherapy proves more effective for young adults
11. Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... by physicians, announced today the launch of a free, public-facing tool for analyzing ... Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers and ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management Association (RBMA) ... as its new executive director. Mr. Still was selected through a careful months-long search ... as he is known to our members, has been a part of building the ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... ... With expansion and efficiency in mind, Patten Seed Company completed relocation of ... opened in Marshallville in 2006, and a bagging and shipping facility has been in ... Patten Seed operations to the Middle Georgia location from their previous home in Lakeland, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... FRANCISCO , March 28, 2017 ...  is expected to reach a value of USD 4.5 ... Grand View Research, Inc. Proper closure of injured tissues ... structure and function. Postoperative leakages occur in 3% to ... complication. They are responsible for one third of postoperative ...
(Date:3/27/2017)... The National University of Singapore (NUS) ... company, signed a Memorandum of Understanding (MOU) recently ... the region. Under this MOU, ... Technology (BIGHEART) at NUS and Holmusk will establish ... healthcare IT and medical device development. These include ...
(Date:3/27/2017)... WAUKESHA, Wis. , March 27, 2017  A ... one of only four freestanding hospitals in the country ... in plastic and reconstructive surgery, concluded that the Surfacide ... effective and integral component in reducing bacterial pathogens not ... The findings were published at the American Burn Association,s ...
Breaking Medicine Technology: